Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jamie Miller

Nurse Practitioner, Family Madisonville, KY Nurse Practitioner

NPI 1184646630 CMS profile 11242934

800 Hospital Dr, Madisonville, KY 42431

Open in the dashboard

General payments

$18,424

915 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jamie Miller of Madisonville, KY is reported in the CMS Open Payments database as having received $18,424 across 915 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,038 161
2024 General $3,036 185
2023 General $4,040 173
2022 General $4,757 148
2021 General $3,553 248

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jamie Miller
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jamie Miller were reported at $3,038. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jamie Miller Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $3,553 $124 $35–$379 $132
2022 $4,757 $141 $44–$430 $149
2023 $4,040 $154 $49–$476 $160
2024 $3,036 $165 $51–$504 $164
2025 $3,038 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Mannkind Corporation $4,599 173 payments
  2. Medtronic, Inc. $2,864 86 payments
  3. Novo Nordisk Inc $1,646 107 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $1,107 69 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $1,003 48 payments
  6. Corcept Therapeutics $1,001 58 payments
  7. Lilly USA, LLC $964 63 payments
  8. Insulet Corporation $717 50 payments
  9. Abbott Laboratories $652 33 payments
  10. Tandem Diabetes Care, Inc. $624 32 payments
  11. Other $3,246 196 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $15,146 900 payments
  2. Travel and Lodging $2,411 12 payments
  3. Consulting Fee $796 1 payment
  4. Gift $59 1 payment
  5. Education $11 1 payment
Products named General payments · program years 2021–2025
  1. AFREZZA $4,599 173 payments
  2. MINIMED 780G $2,388 53 payments
  3. Ozempic $1,359 89 payments
  4. RYBELSUS $1,311 87 payments
  5. Kerendia $1,003 48 payments
  6. Korlym $1,001 58 payments
  7. Omnipod $717 50 payments
  8. t:slim X2 Insulin Pump with Control-IQ $624 32 payments
  9. JARDIANCE $604 41 payments
  10. SOLIQUA 100/33 $435 26 payments
  11. Other $7,562 455 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 110 drugs

Part D claims

9,848

Median for Nurse Practitioner: 389

Drug cost

$4,608,888

Median for Nurse Practitioner: $21,885

Branded share of claims

71.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 621 $719,731
Mounjaro Tirzepatide Brand 581 $690,317
Trulicity Dulaglutide Brand 378 $437,702
Jardiance Empagliflozin Brand 353 $317,876
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 306 $285,937
Tresiba Flextouch U-100 Insulin Degludec Brand 222 $122,814
Humulin R U-500 Insulin Regular, Human Brand 79 $112,699
Novolog Flexpen Insulin Aspart Brand 398 $109,843
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 124 $106,665
Farxiga Dapagliflozin Propanediol Brand 176 $106,525

The 10 drugs with the highest cost, of 110 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$74,079

Medicare's payments for the services billed

Medicare patients

363

Average age 69

Services billed

5,155

223 women, 140 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 46%
Arthritis 44%
Ischemic heart disease 38%
Depression 24%
Heart failure 21%
COPD 21%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
JARDIANCE
$411 353 —
Korlym
$316 — —
AFREZZA
$281 29 —
LEQVIO
$232 — —
Ozempic
$120 621 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

915 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Kentucky

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record